The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT).
about
Gene therapy for carcinoma of the breast: Genetic toxinsStructures of nitroreductase in three states: effects of inhibitor binding and reductionA mammalianized synthetic nitroreductase gene for high-level expressionAntibody-directed enzyme prodrug therapy (ADEPT) for cancer.The study of NADPH-dependent flavoenzyme-catalyzed reduction of benzo[1,2-c]1,2,5-oxadiazole N-oxides (benzofuroxans).Toward a high-throughput screening platform for directed evolution of enzymes that activate genotoxic prodrugs.Recent developments in the design of bioreductive drugsThe use of clostridial spores for cancer treatment.Reduction of polynitroaromatic compounds: the bacterial nitroreductases.Glial Cells and Their Function in the Adult Brain: A Journey through the History of Their Ablation.Suicide gene therapy for graft-versus-host disease.Novel compounds to combat trypanosomatid infections: a medicinal chemical perspective.Conditional ablation of neurones in transgenic mice.Translating antibody directed enzyme prodrug therapy (ADEPT) and prospects for combination.Enhanced efficacy of Escherichia coli nitroreductase/CB1954 prodrug activation gene therapy using an E1B-55K-deleted oncolytic adenovirus vector.DNA sense-and-respond protein modules for mammalian cells.Gene transfer in haematological malignancy.Understanding the broad substrate repertoire of nitroreductase based on its kinetic mechanism.Inhibition of myc-dependent breast tumor formation in transgenic mice.Selective ablation of olfactory receptor neurons without functional impairment of vomeronasal receptor neurons in OMP-ntr transgenic mice.Nitroreductase-mediated cell ablation is very rapid and mediated by a p53-independent apoptotic pathway.Gene transfer and the treatment of childhood cancer.Targeting enzymes to cancers--new developments.Pharmacomicrobiomics: exploiting the drug-microbiota interactions in anticancer therapies.
P2860
Q24797867-30E5CACD-B7E8-4BA6-A12C-C59E82CB516CQ27637446-0FAB19A1-9CDB-477D-A978-B46FCFAC4881Q33497608-C60A274D-F9BF-408F-BB02-EDFEB230BA47Q34577226-0E440E9D-D5BF-4DD6-B232-42D635008031Q34835541-F88B07DF-5CBB-4D01-B47B-46257B0D7DCFQ35201410-4638B1E3-61DC-464C-878D-1FB25F7A84BBQ36292017-316775AE-00F8-4AE3-B9A9-B4791C8CC03FQ36565145-AEEBDF51-2D9E-4B21-AE87-97761115B567Q37114805-09DA62DF-0FF8-4A53-9B64-F1272014CB9CQ37637570-EA003A8E-94D7-4CC0-A640-8820CCD2AA0BQ37773293-95F3B7F8-8F84-49B2-8C8D-70B0DD4F0045Q37856305-20E9E8E5-6BEF-4D3A-BD14-4842A6EEC4EAQ38301222-6739345E-A7EE-4B0F-9563-A936737FFB01Q38979784-199DFE4D-4475-4218-B6FC-AE8533657D31Q40551469-521DF572-BD05-4103-A4E9-5C1DC6B63B59Q40989999-04010482-E85A-4B8F-93C0-E0EC1B32FB9AQ41337488-A0184C7F-B6E8-4212-AFE9-0E8CC0DE6F1CQ41942807-0F4A7CBC-2780-4602-9AF1-3665590DBC91Q43892058-9A8B10E7-9444-4548-8C82-6815D26762CFQ44256152-DEA9B72D-7B1B-43A9-BD6F-7AB5C867F339Q45862524-981BC89D-376C-4AB5-BF63-C3EE05B7FDA6Q45887195-CB8209A1-9E63-42EC-905F-AA956065BFF6Q53619323-08463906-79BE-407D-869F-1A0F6A3AEF13Q55040688-6F32FBE6-07AF-4F55-9B60-2F3773B6BEB3
P2860
The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT).
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年学术文章
@wuu
1993年学术文章
@zh-cn
1993年学术文章
@zh-hans
1993年学术文章
@zh-my
1993年学术文章
@zh-sg
1993年學術文章
@yue
1993年學術文章
@zh
1993年學術文章
@zh-hant
name
The bioactivation of CB 1954 a ...... nzyme prodrug therapy (ADEPT).
@en
type
label
The bioactivation of CB 1954 a ...... nzyme prodrug therapy (ADEPT).
@en
prefLabel
The bioactivation of CB 1954 a ...... nzyme prodrug therapy (ADEPT).
@en
P2093
P356
P1476
The bioactivation of CB 1954 a ...... nzyme prodrug therapy (ADEPT).
@en
P2093
P2888
P304
P356
10.1007/BF00689810
P577
1993-06-01T00:00:00Z
P6179
1030870237